



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

GAL-ON ET AL.

Serial No.: 09/647,952

Filed: December 6, 2000

For: Recombinant Potyvirus Construct
And Use Thereof

Examiner: Dr. Georgia Helmer

§
§
§
§
§
§
§
§
§
§
§

Group Art Unit: 1638

Attorney
Docket: 1686/12

TRANSMITTAL OF APPEAL BRIEF


Commissioner of Patents and Trademarks
Alexandria, VA 22313

Dear Sir:

Transmitted herewith in triplicate is a corrected APPEAL BRIEF in this application with respect to the Notice of Appeal filed on January 15, 2004.

The fee for Appeal Brief was submitted upon filing of the Appeal Brief on July 19, 2004. If however, this fee was not charged to our account, authorization is hereby granted to charge Account No. 06-2140 any additional fees required. A duplicate copy of this transmittal letter is attached.

Respectfully submitted,



Mark M. Friedman
Attorney for Applicant
Registration No. 33,883

Date: August 29, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

GAL-ON ET AL.

Serial No.: 09/647,952

Filed: December 6, 2000

For: Recombinant Potyvirus Construct
And Use Thereof

Examiner: Dr. Georgia Helmer



§
§
§
§
§
§
§
§
§
§
§
§

Group Art Unit: 1638

Attorney
Docket: 1686/12

TRANSMITTAL OF APPEAL BRIEF


Commissioner of Patents and Trademarks
Alexandria, VA 22313

Dear Sir:

Transmitted herewith in triplicate is a corrected APPEAL BRIEF in this application with respect to the Notice of Appeal filed on January 15, 2004.

The fee for Appeal Brief was submitted upon filing of the Appeal Brief on July 19, 2004. If however, this fee was not charged to our account, authorization is hereby granted to charge Account No. 06-2140 any additional fees required. A duplicate copy of this transmittal letter is attached.

Respectfully submitted,



Mark M. Friedman
Attorney for Applicant
Registration No. 33,883

Date: August 29, 2005



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

GAL-ON ET AL.

Serial No.: 09/647,952

Filed: December 6, 2000

For: Recombinant Potyvirus Construct
And Use Thereof

Examiner: Dr. Georgia Helmer

§
§
§
§
§
§
§
§
§
§
§

Group Art Unit: 1638

Attorney
Docket: 1686/12

Commissioner of Patents and Trademarks
Alexandria, VA 22313

ATTENTION: Board of Patent Appeals and Interferences

CORRECTED APPEAL BRIEF

Dear Sir:

This is in furtherance of the Notice of Appeal filed in this case on January 15, 2004.

The fees required under § 1.17(f) and any required petition for extension of time for filing this brief and fees therefor are dealt with in the accompanying TRANSMITTAL OF APPEAL BRIEF.

This brief is transmitted in triplicate.

09/07/2005 MBIZUNES 00000054 062140 09647952

02 FC:2402 250.00 DA

This brief contains these items under the following headings and in the order set forth below:

- I. REAL PARTY IN INTEREST
- II. RELATED APPEALS AND INTERFERENCES
- III. STATUS OF CLAIMS
- IV. STATUS OF AMENDMENTS
- V. SUMMARY OF INVENTION
- VI. ISSUES
- VII. GROUPING OF CLAIMS
- VIII. ARGUMENTS
 - X OBJECTIONS ACCORDING TO 37 CFR § 1.75 (c)
 - X REJECTIONS UNDER 35 U.S.C. §112
 - X REJECTIONS UNDER 35 U.S.C. §102
- IX. APPENDIX OF CLAIMS INVOLVED IN THE APPEAL

I. REAL PARTY IN INTEREST

The real party in interest in this case is:

Virogene Ltd.

Hod Ha'Sharon

Israel

II. RELATED APPEALS AND INTERFERENCES

There are no related appeals and interferences in this case.

III. STATUS OF CLAIMS

Claims 1,2,6, 10-12, 15 and 20 are currently pending and stand rejected.

All other claims have been cancelled.

IV. STATUS OF AMENDMENTS

In a response [filed 30 April, 2003] to a previous non-final rejection, claims 1,2,6,10,11, 12, 15 and 20 were amended.

In a final action dated July 30, 2003, the Examiner acknowledges these amendments.

V. SUMMARY OF INVENTION

The present invention generally relates to a recombinant potyvirus infectious nucleic acid construct useful for providing protection against viral infection in plants (page 5 lines 12-13) and to a recombinant virus harboring said construct (page 5 line 17, page 11 lines 3-4). More specifically, the present invention relates to a recombinant potyvirus infectious construct containing an HC – Pro gene whose sequence coding for the conserved FRNK box contains an (Arg) to Isoleucine (Ile) substitution (page 11 lines 1-2, Figure 1 clone (d)).

Most relevant to the current appeal are those embodiments of the invention which employ a ZYMV recombinant potyvirus infectious nucleic acid construct (Figure 1 clone (d)).

The present invention further relates to a method for the production of a mild strain of potyvirus utilizing the above mentioned construct (page 9 lines 1-21) and to a method for protecting plants from viral infection (page 4 lines 22-25, page 9 line 22 to page 10 line 4) and for transient expression of foreign nucleic acid (genes) in plants (page 5 line 8, page 13 lines 9-22) using said construct. Preferably, the present invention relates to a method for cross protection of cucurbits against ZYMV infection (page 4 lines 16-17, page 12 line 25 to page 13 line 8).

VI. ISSUES

The issues presented for review are as follows:

Objections to claims 6, 11, 12 and 20 according to 37 CFR § 1.75 (c) and MPEP § 608.01 (n) as failing to meet the requirement for alternative language.

Rejection of claims 1, 2, 6, 10-12, 15 and 20 as being indefinite according to 35 U.S.C. 112, second paragraph.

Rejection of claims 1-6, 10-12, 15 and 20 as being anticipated by Huet et al., (*Mutations in the helper component protease gene of zucchini yellow mosaic virus affect its ability to mediate aphid transmissibility*, J. General Virology (1994) 75:1407-1414; henceforth, "Huet") under 35 U.S.C. 102(b).

VII. GROUPING OF CLAIMS

For purposes of the objections according to 37 CFR § 1.75 (c) and MPEP § 608.01 (n):

claims 6, 11, 12 and 20 are grouped together.

For purposes of the §112, second paragraph rejections:

independent claim 1 and dependent claims 2, 11, and 15 are grouped together and will stand or fall as a group;

dependent claims 6, 10, 12 and 20 are each grouped separately and their separate evaluation is respectfully requested.

For purposes of the §102(b) rejections:

independent claim 1 and dependent claims 2, 11 and 15 are grouped together and will stand or fall together;

dependent claims 6, 10, 12 and 20 are each presented separately and may stand independently of the other claims.

VIII. ARGUMENTS

OBJECTIONS ACCORDING TO 37 CFR § 1.75 (c)

AND MPEP § 608.01 (n)

The Examiner has objected to multiply dependent claims 6, 11, 12 and 20 citing 37 CFR § 1.75 (c) and MPEP § 608.01 (n) which deal with multiply dependent claims. Specifically, the Examiner has objected to the format “any of claims X,Y and Z” as a means of indicating alternative (i.e. “or”) dependence.

The Examiner’s objection is not well taken. MPEP § 608.01 (n) clearly states:

One or more claims may be presented in dependent form, referring back to and further limiting another claim or claims in the same application. Any dependent claim which refers to more than one other claim (“multiple dependent claim”) shall refer to such other claims in the alternative only. (emphasis added)

37 CFR § 1.75 (c) contains similar language:

“(c) One or more claims may be presented in dependent form, referring back to and further limiting another claim or claims in the same application. Any dependent claim which refers to more than one other claim (“multiple dependent claim”) shall refer to such other claims in the alternative only. ...”(emphasis added)

Webster’s New world Dictionary (Second College edition (1976) William Collins + World Publishing Co. Inc.) defines any as:

“one, no matter which, of more than two”

Thus, using the commonly accepted definition of any, it is clear that a multiply dependent claim in the form “any of claims X,Y and Z” refers to each of claims X,Y and Z alternatively. For this reason, such a claim is counted as three claims for purposes of fee calculation. The triple payment is reflective of the Examiner’s effort in evaluating three alternative claims.

Thus, Applicant respectfully, but firmly, asserts that the language of claims 6, 11, 12 and 20 as currently on file meets the criteria of referring to other claims *"in the alternative only"* as required by the MPEP and 37 CFR. The linguistic formula employed is analogous to that found in Markush groups which employ the word "and" although they describe "or" logic. The Examiner's objection is refuted.

All objections are refuted. If the appeal board chooses to uphold the Examiner's objection(s), a clear assurance that use of the word "or" in a claim will not compromise the legal validity of the claim is respectfully requested. Once such an assurance is of record in this case, Applicant would, in order to expedite prosecution, consider making the requested linguistic changes.

REJECTIONS UNDER 35 U.S.C. §112, SECOND PARAGRAPH

The Examiner has rejected claims 1, 2, 6 and 10-12, 15 and 20 under 35 U.S.C. §112, second paragraph as being indefinite because the term "single mutation" is indefinite in the absence of a "frame of reference".

The Examiner cites Rieger et al. [Glossary of Genetics and cytogenetics, 1976] to establish that:

".... the standard of reference for a mutant is the so called wild type, either the state of organisms as they are found in nature or arbitrarily chosen."

Applicant notes, for the record, that it is only in the current office action that it became clear that a frame of reference is being requested for the entire genomic sequence.

With respect to independent claim 1 and dependent claims 2, 11, and 15, the Applicant concedes that no frame of reference has been established for all of the species of potyvirus.

With respect to dependent claims 6, 10 and those portions of claims 12 and 20 which depend therefrom, the Examiner's rejection is not well taken. Throughout the prosecution, the Examiner has relied heavily upon Huet et al. (1994; J. Gen. Virol (75);1407-14; hereinafter Huet).

Huet is currently the sole prior art reference employed by the Examiner in formulating a 102 rejection (see below). During a recent telephone interview [summary attached as appendix A], the Examiner was made aware that Huet cited, in 1994, a published wild type sequence for ZYMV (Balint et al. (1990) Proceedings of the VIIIth International Congress of Virology (abstract) Berlin; p472).

Applicant asserts Huet's reference to Balint et al (1990) indicates that the required frame of reference for claim 6 and all claims which depend therefrom was widely available and generally acknowledged by those of ordinary skill in the art at the time the instant application was filed. Thus, one of ordinary skill, such as Huet, would have been able, without undue effort, to obtain the wild type sequence published by Balint for purposes of ascertaining if the claimed "single mutation" criteria were being met by a disputed ZYMV strain. In summary, the required frame of reference was readily apparent and available to those of ordinary skill 10 years before the time the application was filed in December 2000. The fact that the Balint reference was uncovered by

the Examiner in the course of Examination indicates that no undue effort is required to find it. Alternately, publication of the Huet reference in 1994 served to call attention to the Balint reference and make the required frame of reference publicly available six years before the filing date of the instant application.

Admittedly, Balint does not provide an electronic (read searchable) copy of the sequence. However, the full sequence was first published in 1995 [Wisler, G.C., Purcifull, D.E. and Hiebert, E. "Characterization of the P1 protein and coding region of the zucchini yellow mosaic virus" J of General Virology 76 37-45 (1995) [ACCESSION No. (L31350)]. (See *appendix B*) This publication made the required frame of reference even more "readily available" to "one of ordinary skill in the art" five years before the filing date of the instant application.

In summary, one of ordinary skill in the art would both understand what is the wild type frame of reference for ZYMV and be able to access an electronically searchable copy for purposes of comparison on the filing date of the application. Therefore, those of ordinary skill would not have thought that the Wild Type frame of reference would be at issue in December 2000 when the instant application was filed.

Applicant asserts that the Examiner's suggestion that failure to specifically define L31350 as the frame of reference represents an "error in judgment" on the part of the Applicant is indicative of an inability to grasp the

state of the art and the level of knowledge of one of “ordinary skill in the art” at the time the application was filed.

The Examiner has asserted that the “wide availability” of the Wisler reference has not been established. Such an assertion is not well taken. The Huet reference appears in the same journal [J. of Gen. Virol.] as the Wisler reference. Further, the required “frame of reference” is available through the NCBI search engine on the Internet [Appendix B].

Applicant notes, for the record, that the currently pending office action contains no request for a SEQ. ID. NO. Thus, the requisite frame of reference for a ZYMV with a single mutation is supplied by the Wisler reference. The mutation itself is described in detail in the body of claim 1, from which claim 6 depends.

The Examiner’s rejection of claims 6, 10 and those portions of claims 12 and 20 which depend therefrom under 35 U.S.C. §112 is traversed.

A stipulation that these claims contain allowable subject matter is sought.

REJECTIONS UNDER 35 U.S.C. §102 (b)

The Examiner has rejected claims 1, 2, 6, 10-12, 15 and 20 under 35 U.S.C. §102 (b) as being anticipated by Huet.

Because the Applicant has not overcome the §112 second paragraph rejections for independent claim 1 and dependent claims 2, 11 and 15, no argument against the §102 (b) rejection of those claims is offered.

The Examiner's rejection of dependent claims 6 and 10 and those portions of claims 12 and 20 which depend therefrom is not well taken.

Rejection of these claims as being anticipated by Huet in a previous office action induced the Applicant to offer substantive amendments which greatly reduced the scope of the claimed invention. Specifically, the phrase "a single mutation" meaning one and only one mutation was introduced into claim 1.

Huet teaches against what is claimed by teaching a ZYMV strain characterized by two mutations. Applicant asserts "a single mutation" as instantly claimed, is patentably distinct from the Huet teachings. Huet fails to hint or fairly suggest any necessity or advantage for isolating the claimed ARG to ILE mutation in the FRNK box from the "PAK" mutation described in figure 2; line 1 (p1410) of the Huet reference.

The Examiner's attempt to obfuscate the issue by referring to a "frame of reference" in the context of the 102(b) rejection is resented. Applicant's arguments concerning frame of reference are set forth hereinabove under the 112 second paragraph traversal.

Claim 6, which depends from claim 1, is directed towards a construct containing a single mutation. Applicant strongly asserts that this stipulation of "a single mutation" establishes metes and bounds which clearly exclude the 2-mutant construct described by Huet.

While the Huet reference is definitely appropriate to use in examining the instant application, any assertion that Huet anticipates the instantly claimed invention must ultimately be rejected. Huet observed certain properties in a mutant

strain with 2 mutations. However, Huet does not hint or fairly suggest that the Arg to Ile mutation in the FRNK box ALONE is necessary or desirable to produce a:

“...construct is capable of systemic infection of a plant;

wherein said systemic infection induces a mild form of disease; and wherein said systemic infection affords cross protection against a subsequent potyvirus infection.”

as instantly claimed.

Thus, the Examiner’s assertion that “... the sequence taught by Huet et. al. meets the all of the limitations of the claims...” is erroneous on its face.


The Examiner’s rejection of claims 6 and 10 and those portions of claims 12 and 20 which depend therefrom under 35 U.S.C. §102 (b) is traversed.

All rejections of claims 6 and 10 and those portions of claims 12 and 20 which depend therefrom are traversed.

All objections are refuted.

Claims 6 and 10 and those portions of claims 12 and 20 which depend therefrom contain patentable subject matter. Stipulation of allowable subject matter is respectfully requested so that Applicant can undertake to re-draft the claims in independent language.

Respectfully submitted,



Mark M. Friedman
Attorney for Applicant
Registration No. 33,883

Date: August 29, 2005

IX. APPENDIX OF CLAIMS INVOLVED IN THE APPEAL

The text of the claims on appeal is:

- 1) (Previously Entered) A recombinant potyvirus infectious nucleic acid construct useful for plant cross protection, the construct comprising a full length clone characterized by a single mutation, said single mutation residing in its HC- Pro gene conserved FRNK box encoding sequence said single mutation encoding a substitution of Arg by Ile;
wherein the construct is capable of systemic infection of a plant;
wherein said systemic infection induces a mild form of disease; and
wherein said systemic infection affords cross protection against a subsequent potyvirus infection.
- 2) (Previously Entered) A recombinant construct according to claim 1 wherein the nucleic acid is cDNA or an RNA transcript.
- 3-5) (Cancelled)
- 6) (Previously Entered) A recombinant potyvirus infectious nucleic acid construct according to any of claims 1 and 2 wherein the potyvirus is ZYMV.
- 7-9) (Cancelled)

10) (Previously Entered) A recombinant construct according to claim 6 wherein said cross protection is against severe strains of ZYMV.

11) (Previously Entered) A recombinant potyvirus infectious nucleic acid construct according to any of claims 1, 2 and 6 wherein the potyvirus is selected from BCMV, BYMV, BtMV, MWMV, OYDV, PRSV, PStV, PepMoV, PVMV, CGVBV, GEV, ISMV, JGMV, LYSV, LMV, MDMV, PPV, PVA, PVV, PVY, SCMV, SPFMV, TEV, TVMV, TBV, TuMV, WMV-2, YMV and ZYFV.

12) (Previously Entered) A recombinant construct according to any of claims 1, 2, 6, 10 and 11 further useful for the transient expression of foreign nucleic acid in plants wherein the full length clone has, in any position, a sequence of DNA or RNA inserted into the full length clone.

13-14) (Cancelled)

15) (Previously Entered) A method for introducing foreign nucleic acid into plants comprising infecting a plant with a recombinant potyvirus infectious nucleic acid construct as defined in claim 11.

16-19) (Cancelled)

20) (Previously Entered) Compositions for plant inoculation or for transient expression of foreign nucleic acid in plants containing, as an active ingredient, the recombinant construct according to any of claim 1, 2, 6, 10, 11 and 12.

APPENDIX A TO SUPPLEMENTARY BRIEF

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:	§	
	§	
GAL-ON ET AL.	§	
	§	
Serial No.: 09/647,952	§	
	§	
Filed: December 06, 2000	§	Group Art Unit: 1638
	§	
For: RECOMBINANT POTYVIRUS	§	Attorney
CONSTRUCT AND USE	§	Docket: was 1268-107
THEREOF	§	now 1686/12
Examiner: DR. GEORGIA HELMER	§	

Because a written authorization for use of e-mail has been provided in this case in accord with MPEP 502.03, communications via Internet e-mail, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used. In such case, a printed copy of the Internet e-mail communications MUST be given a paper number, entered into the Patent Application Locating and Monitoring System (PALM) and entered in the patent application file.

TELEPHONE INTERVIEW SUMMARY

A telephone interview was conducted on Wed June 30 at 9 am Washington D.C. time. The USPTO was represented by Elizabeth McElwain and Georgia Helmer. The Applicant was represented by Sinai Yarus of Mark Friedman Ltd.

Current Status

An appeal brief was filed by Applicant's representative after a final action was received. The Examiner responded by issuing a non-final action. Applicant may either respond or request re-instatement of the appeal. Applicant requested, and was granted, an interview for the express purpose of avoiding re-instatement of appeal.

Substantive issues

APPENDIX A TO SUPPLEMENTARY BRIEF

Claim 1 as currently on record reads:

“A recombinant potyvirus infectious nucleic acid construct useful for plant cross protection, the construct comprising a full length clone characterized by a single mutation, said single mutation residing in its HC- Pro gene conserved FRNK box encoding sequence said single mutation encoding a substitution of Arg by Ile; ...

The Examiner has rejected the claim stating that a “frame of reference” for the whole “full length clone” is required.

While claim 1 as currently on file is for all potyviruses, the original appeal brief indicated that:

“Independent claim 1 and dependent claims 2, 11, 12, 15 and 20 are grouped together and will stand or fall together while dependent claims 6 and 10 are presented as a separate group which may stand independently of the other claims.”

Claims 6 and 10 relate specifically to ZYMV as a subset of potyviruses.

The interview was directed primarily towards trying to agree on an acceptable frame of reference for claim 6.

Both sides referred to the Huet et al. reference (1994; J. Gen. Virol (75);1407-14) reference which is the sole prior art reference currently employed by the Examiner in formulating a rejection.

Applicant pointed out that Huet, being “one of ordinary skill in the art” in 1994, was aware of a published wild type sequence for ZYMV and cited same

APPENDIX A TO SUPPLEMENTARY BRIEF

(Balint et al. (1990) Proceedings of the VIIIth International Congress of Virology (abstract) Berlin; p472).

Applicant asserted that the Huet reference refers to Balint et al (1990) which discloses the full sequence of ZYMV making it publicly available and establishing the required frame of reference for claim 6. Applicant further argued that one of ordinary skill, such as Huet, would have been able, without undue effort, to obtain the wild type sequence published by Balint. As such, the required frame of reference was readily apparent and available to those of ordinary skill 10 years before the time the application was filed in December 2000.

The Examiner argued that Balint does not provide an electronic (read searchable) copy of the sequence so that the required frame of reference is not available.

Applicant asserted that the full sequence was first published in 1995 [Wisler,G.C., Purcifull,D.E. and Hiebert,E. "Characterization of the P1 protein and coding region of the zucchini yellow mosaic virus" J of General Virology 76 37-45 (1995) [ACCESSION No. L31350)]. (*See additional attached document downloaded from NCBI*) Applicant further asserted that this publication made the required frame of reference "readily available" to "one of ordinary skill in the art" one year before the filing date of the instant application. This means that one of ordinary skill in the art would both understand what is the wild type frame of reference and be able to access an electronically searchable copy for purposes of comparison on the filing date of the application. Applicant further asserted that

APPENDIX A TO SUPPLEMENTARY BRIEF

those of ordinary skill would not have thought that the Wild Type frame of reference would be at issue in December 2000 when the application was filed.

The Examiner asserted that the “wide availability” of the Wisler Reference was not established. Applicant responded that while the J. of Gen. Virol. is not as widely distributed as the New York Times, it is well known to virologists of ordinary skill (e.g. Huet).

The Examiner asserted that even if the Wisler Reference were placed on the record it would still not establish the requisite frame of reference because it is not in the specification. Applicant countered by saying that the file wrapper in its entirety is available for inspection in cases where the meaning of a claim is at issue.

Applicant offered to file an IDS under Title 37 § 1,97(c)(2). (IDS after office action but before final action or notice of allowance) to get the Wisler reference “On the Record”. Examiner asserted that this would not establish the requisite frame of reference.

The Examiner suggested alternate strategies for establishing the requisite frame of reference including:

- 1) Deposit in a recognized depository of ZYMV-AG1. The Examiner stipulated that introduction of a deposit number for this strain into the specification would be permissible because the strain was mentioned in the application as originally filed (e.g. in claim 7, now cancelled).

- 2) Submit of an affidavit from a disinterested party, even a colleague from the same institution as the inventor. Disinterested was defined as anyone that hold no rights in the application by virtue of assignment and is not an inventor. The affidavit should state that “At the time of filing of the application it was

APPENDIX A TO SUPPLEMENTARY BRIEF

well known that L31350 is the wild type sequence for ZYMV and thus establishes the appropriate frame of reference.”

Applicant’s representative inquired as to the time frame for processing a response and was informed that it was unlikely that any action in this case would be taken before the July 19 deadline for re-instating the appeal. This is apparently because the case is not currently the subject of a final action.

Applicant’s representative undertook to communicate the substance of the interview to the Applicant.


Interview was conducted and concluded amicably, but without resolving the substantive issue of frame of reference.

This summary is not a response to the currently pending office action in this case and does not prejudice the Applicant’s right to re-instate the appeal.

Interview duration; approximately 40 minutes

UNSIGNED E-MAIL TRANSMISSION

Dr. Sinai Yarus
Mark Friedman Ltd.



Taxonomy

Clear

Data

Get Subsequence

Links

```

FEATURES
    source                Location/Qualifiers
                        1..9593
                        /organism="Zucchini yellow mosaic virus"
                        /mol_type="genomic RNA"
                        /strain="California"
                        /db_xref="taxon:12232"
    5'UTR              1..140
                        /note="leader sequence"
    CDS                140..9382
                        /codon_start=1
                        /product="polyprotein"
                        /protein_id="AAA65559.1"
                        /db_xref="GI:466348"

```

CDS

file://C:\Documents%20and%20Settings\nomi\Local%20Settings\Temporary%20Inter... 7/18/2004

```

VRNVRPDLEETLLYMAGVEVVSTQAKSAVQIQFEKI IAVLALLTMCFDAERSDAIFKI
LTKLKT VFGTVGETVRLQGLEDI ESLEDDKRLTIDFDINTNEAHSSTTFDVHFDDWWN
RQLQONRTVPHYRTTGKFLEFTRNTAAAFVANEIASSSEGEFLVRGRVGS GKSTSLPAH
LAKKGKVLLLEPTRPLAENVSRQLAGDPFFQNVTLRMRGLSCFGSSNITVMTSGFAFH
YYVNNPHQLMEFDFVII DECHVTDSATIAFNALKEYNFAGKLIKVSATPPGRECDFD
TQFAVKVKTEDHLSFHAFVGAQKTGSNADMVQHGNILVYVASYNEVDMLSKLLTERQ
FSVTKVDGRTMQLGKTTIETHGTSQKPHFIVATNI IENGVTLDVECVVDFGLKVGRRRT
GQRNRCVRYNKKSVSYGERIQRLGRVGRSKPGTALRIGHTEKG IETIPEFIATEAAAL
SFAYGLPVTTTHGVSTNILGKCTVKQMKCALNFELTPFFTTHLRHDGSMHPLIHEELK
QFKLRDSEMVLNKVALPHQFVSQWMDQSEYERIGVHVQCHESNSIPFYTNGIPDKVYE
RIWKCIQENKNDVFGKLSSACSTKVSYTLSTDPAALPRTIAIIDHLLAEEMMKRNHF
DTISSAVTGYSFSLAGIADSFRRKRYMRDYTAHNIAILQQAQALLEFN SKNVNINNL
DLEGIGVIKSVVLQSKQEVSSFLGLRGKWDGKKFANDVILAIMTLLGGGWFMWEYFTK
KINEPVRVESKKRRSQKLKFRDAYDRKVGREIFGDDDTIGRTFGEAYTKRGKVKGNNN
TKGMGRKTRNFVHLYGVEPENYSFIRFVDPLTGHTLDESTHTDISLVQEEFGSIREKF
LENDLISRQSIINKPGIQAYFMGKGTEEALKVDLTPHPVLLLCRNTNAIAGYPERENE
LRQTGTPVKVSFKDVPEKNEHVELESKSIYKGVDRYNGISTIVCQLTNDSDGLKETMY
GIGYGPIIITNGHLFRKNNGTLLVRSWHGEFIVKNTTTTLKVHFIEGKDVVLVRMPKDF
PPFKSNASFRAPKREERRCLVGTNFQEKSLRSTVSESSMTIPEGTGSYWIHWISTNEG
DCGLPMVSTTDGKIIGVHGLASTVSSKNYFVPFTDDFIATHLSKLDLDTWTQHWLWQP
SKIAWGTLNLVDEQPGPEFRISNLVKDLFTSGVETQSKRERWVYESCEGNLRAVGTAQ
SALVTKHVVGKGCFFEEYLQTHAEASAYFRPLMGEYQPSKLNKEAFKKDFFKYKNPV
TVNQLDHDKFLGAVDGVIRMMCDFEFNECRFITDPEEIYNSLNMKAAIGAQYRGKKKE
YFEGLDLDFDRERLLFQSCERLFNGYKGLWNGSLKAE LRPLEKVRANKTRTFTAAPIDT
LLGAKVCVDDFNNEFYRKNLKCPWTVGMTKFGYGGWDKLMRSLPDGWLYCHADGSQFDS
SLTPALLNAVLIIRSFYMEDWWVGQEMLENLYAEIVYTPILAPDGTIFKKFRGNNSGQ
PSTVVDNTLMVVISIYYACMKFGWNCEEIENKLVFFANGDDLILAVKDEDSGLLDNMS
SSFCEGLNLYDFSERTHKREDLWFMSHQAMLVDGMYTPKLEKERIVSILEWDRSKEIM
HRTEAICAAMIEAWGHTELLQEIRKFYLFVFEKEEVRELAALGKAPYIAETALRKLYT
DKGADTSELARYLQALHQDIFFEQGDVMLQSGTQPTVADAGATKKDKEDDKGKNKDV
TGSGSGEKTVAAVTKDKDVNAGSHGKIVPRLSKITKKMSLPRVKGNVILDIHLLLEYK
PDQIELYNTRASHQQFASWFNQVKTEYDLNEQQMGVVMNGFMVWCIENGTS PDINGVW
VMDGNEQVEYPLKPIVENAKPTLRQIMHHFSDAAEAYIEMRNAEAPYMPRYGLLRNL
RDRSLARYAFDFYEVNSKTPERAREAVAQMKAAALSNVSSRLFGLDGNVATTSEDTER
HTARDVNRNMHTLLGVNTMQ"

```

```

mat peptide 140..1051
               /product="P1 protease"
mat peptide 1052..2437
               /product="P2 HC-protease"
               /function="helper component-protease"
mat peptide 2438..3631
               /product="P3 protein"
               /function="unknown"
mat peptide 3632..5533
               /product="cylindrical inclusion protein"
mat peptide 5534..5692
               /product="P6K"
mat peptide 5693..6991
               /product="protease"
               /note="NIa; putative"
mat peptide 5693..6262
               /product="VPg; putative"
mat peptide 6992..8542
               /product="replicase"
               /note="NIB; putative"
mat peptide 8543..9379
               /product="capsid protein"
3'UTR         9379..9593

```

ORIGIN

```

1 aaaattgaaa caaatcacaa agactacaag aatcaacgat caagcaaacg aatttttgaa
61 cgtattttaca aacaagcaat ctaaaactct tacagtatta agaaattctc caatcacttc
121 gtttacttca gacataacaa tggcctccat catgattggt tcaatctctg taccatttgc
181 aaagactgag cagtgtgcaa acactcaagt aagtaatcgg gctaatatag tggcacctgg
241 ccacatggca acatgcccat tgccactgaa aacgcacatg tattacaggc atgagtccaa

```

```
301 gaagttgatg caatcaaaca agagcattga cattctgaac aacttcttca gcaactgacga
361 gatgaagttt aggctcactc gaaacgagat gagcaagctg aaaaagggtc cgagcgggag
421 gatagtcctc cgcaagccga gtaagcagcg ggttttcgct cgtatcgagc aggatgaggg
481 agcacgcaag gaagaggctg ttttcctcga aggaaattat gacgattcca tcacaaattct
541 agcacgtggt cttccacctg ccgtgactca caacgttgat gtgagcttgc gatcaccggt
601 ttacaagcgc acatacaaga aggaaaggaa gaaagtggcg caaaagcaaa ttgtgcaagc
661 accacttaat agcttggtgca cacgtgttct taaaattgca cgcaataaaa atatccctgt
721 tgagatgatt ggcaacaaga agacgagaca tacactcacc ttcaagaggt ttaggggatg
781 ttttggttga aaggtgtcag ttgcgcatga agaaggacga atgcggcaca ctgagatgtc
841 gtatgagcag tttaaattggc ttcttaaagc catttgtcag gtcacccata cagagcgaat
901 tcgtgaggaa gatattaaac caggttgtag tgggtgggtg ttgggcacta atcatacatt
961 gactaaaaga tattcaagat tgccacattt ggtgattcga ggtagagacg acgatgggat
1021 tgtgaacgcg ctggaacagg tgttatttta tagcgaagtt gaccactctt cgtcgcaacc
1081 ggaagttcag ttcttccaag gatggcgacg aatatttgat aagtttaggc ctagcccaga
1141 tcatgtgtgc aaagctgacc acaacaacga ggaatgtggt gagttagcag caatcttttg
1201 tcaggctcta tttccagtag tgaaactatc gtgccaaaaca tgcagagaaa gcttagtaga
1261 agttagcttt gaggaattca aagattcttt gaacgcaaac tttattatcc acaaggatga
1321 atggggtagt ttcaagggaag gctctcaata cgataatatt ttcaaattaa tcaagtggtc
1381 aacacaggca actcagaatc tcaagctctc atctgaagtt atgaaattag ttcagaacca
1441 cacaagcact cacatgaagc aaatacaaga catcaataag gcgctcatga aaggttcatt
1501 ggttgcgcaa gacgaattgg acttagcttt gaaacagctt cttgaaatga ctcagtgggt
1561 taagaaccac atgcacctga ctggtgagga ggcattgaag atgttcagaa ataagcgttc
1621 tagcaaggcc atgataaatc ctagccttct atgtggcaac caattggaca aaaaaggaaa
1681 ttttggtttg ggagaaagag gataccattc caagcgatta ttcaagaact tttcgaaga
1741 agtaatacca agcgaaggat atacgaagta cgtagtgcga aactttccaa atggtactcg
1801 taagttggcc ataggctcat tgattgtacc acttaatttg gataggcac gcaactgcact
1861 acttgagag agtattgaga agaagccact cacatcagcg tgtgtctccc aacagaatgg
1921 aaattatata cactcatgct gctgtgtaac gatggatgat ggaaccccga tgtactccga
1981 gcttaagagc ccgacgaaga ggcacttagt tataggagct tctagtgatc caaagtacat
2041 tgatctgcca gcatctgagg cagaacgcac gtatatagca aaggaagggt attgctatct
2101 cagtattttc ctcgcaatgc ttgtaaatgt taatgagaac gaagcaaagg atttcaccaa
2161 aatgattcgt gatgttttga tccccatgct tgggcagtgg ccttcattga tggatgttgc
2221 aactgcagca tatattctag gtgtattcca tcttgaaacg cgatgcgtg aattacccag
2281 gatccttggt gaccacgcta cacaaccat gcatgtcatt gattcttatg gatcataac
2341 tgttgggtat cacgtgctca agcgtggaac tgccaatcat ttaattcaat ttgcctcaaa
2401 tgatctgcaa agcgagatga aacattacag agttgggtgg acaccaacac agcgcattaa
2461 actcgaggag cagctgatta aaggaatttt caaaccaaaa cttatgatgc agctcctgca
2521 tgatgacca tacatattat tacttggcat gatttcaccc accattcttg tacatatgta
2581 taggatgcgt cattttgagc ggggtattga gatatggatt aagagggatc atgaaatcgg
2641 aaagattttc gtcataatag agcagctcac acgcaagggt gctctggcag aagttcttgt
2701 ggatcaactt aacttgataa gtgaagcttc accacattta cttgaaatta tgaagggttg
2761 tcaagataat cagagggcat acgtacctgc gctggatttg ctaacgatac aagtggagcg
2821 tgagttttca aataaagaac tcaaaaccaa tggctatcca gatttgcagc aaacgctctt
2881 cgatattgag gaaaaaatgt atgcaaagca gctgcacaat tcatggcaag tcaatagctt
2941 gctggaaaaa tctgtgttaa ccgtgcgatt gaagcaattc tcgattttta cggaaagaaa
3001 tttaatccag cgagcaaaaag aaggaaagcg cgcactcttc ctacaatttg ttcacgagtg
3061 ttttatcacg acccgagtac atgcgaagag cattcgcgat gcaggcgtgc gtaaaactaaa
3121 tgaggctctc gtcggaactt gtaaattctt tttctcttgt ggtttcaaaa tttttgcgcg
3181 atgctatagc gacataatat acctgtgtaa cgtgtgtttg gttttctcct tgggtgctaca
3241 aatgtccaat actgtgogca gtatgatagc agcgacaagg gaagaaaaag agagagcgat
3301 ggcaataaaa gctgatgaaa atgaaaggac gttaatgcat atgtaccaca ttttcagcaa
3361 gaaacaggat gatgcgccca tatacaatga ctttcttgaa catgtgcgta atgtgagacc
3421 agatcttgag gaaactctct tgtacatggc tggcgtagaa gttgtttcaa cacaggctaa
3481 gtcagcggtt cagattcaat tcgagaaaaa tatagctgtg ttggcgctgc ttaccatgtg
3541 ctttgacgcc gaaagaagcg atgccatttt caagattttg acaaaactca aaacagtttt
3601 tggtagcggt ggagaaacgg tccgacttca agggcttgaa gacattgaaa gcttggagga
3661 cgataaaaga ctcacaattg attttgatat taacacgaac gaagctcatt cgtcaacaac
3721 atttgatgtc cattttgatg actggtggaa tcggcaacta cagcaaaatc gcacagttcc
3781 acattacagg accacaggca aattccttga atttaccaga aatactgcag cttttgtggc
3841 caatgaaata gcatcatcaa gtgagggaga gttcttagtt agaggacgag taggttcttg
3901 aaaatcaacg agcttacctg cacatcttgc caagaagggt aaggtgttac tactcgaacc
3961 tacacgccct ttggcggaga atgttagtag acagttagca ggtgatcctt tctttcaaaa
4021 cgttacactc agaattgagag ggttaagttg ttttggttca agcaatatta cagtgtgac
4081 gagtggattt gcttttcact actatgttaa caatccacat caattgatgg aatttgactt
```

4141 tgtcatcata gacgagtgcc atgtcacaga cagtgcgacc atagctttca attgtgcact
4201 taaagagtac aacttttctg gcaaattgat taaagtgtct gcaacgccgc cagggagaga
4261 gtgcgatttc gatacgcaat tcgcggtgaa agtcaaaaaca gaggaccatc tttcattcca
4321 tgcattctgtt ggcgcacaga agactgggttc aaatgctgac atgggttcagc atggtaataa
4381 catacttgtg tatgttgcaa gttacaacga agtggacatg ctctctaagt tactcactga
4441 gcgccaattt tcagttacaa aggtagatgg gcgaacaatg cagcttgga aaactaccat
4501 tgaaacgcat ggaactagcc aaaagcccca tttcatagta gctacaaaca tcatcgagaa
4561 tggagtgcag ttggatgttg agtgtgttgt tgattttgga ctaaaagtgg gtgcgagaac
4621 tggacagcga aatcggtgtg tgcgctacaa taagaaatca gttagttaat gagagaggat
4681 tcagcgacta ggaagagtgg ggagatctaa gcctggaact gcattgcgta tagggcacac
4741 agaaaaaggg atcgaaacca ttcctgaatt cattgccaca gaagcagcag ccttatcatt
4801 tgcatatggg cttccagtca ccacacatgg agtttccaca aatatacttg gaaagtgcac
4861 agttaaacag atgaaatgtg ctttgaactt tgagctaact cctttcttca ccactcattt
4921 aatccgtcat gatggtagta tgcattccact aatacacgaa gaattgaagc agttcaaact
4981 cagggatttca gaaatggtgc tcaacaagggt tgcattacct catcaatttg tgagccaatg
5041 gatggatcaa agtgagtatg aacgcattgg agtgcacgtt caatgccatg agagcaacag
5101 catacctttt tacacaaatg gaatacctga taaagtctat gagagaattt ggaagtgcac
5161 acaagaaaac aagaacgatg cggtttttgg taagctttca agtgcttgtt caactaagggt
5221 tagttatata cttagcactg atccagcagc attaccaga actattgcaa tcatcgatca
5281 cctgcttgcc gaggaaatga tgaagcggaa tcacttcgac actatcagct cagctgtaac
5341 gggctattca ttttcccttg ctggaattgc tgattctttc aggaagagat acatgcgcga
5401 ttacacagcg cacaacattg caattctcca acaagcacgt gccagctgc ttgaatttaa
5461 tagtaagaat gtgaacatta acaatctgtc cgatttagaa ggaattggag tcatatagtc
5521 ggtggtgttg caaagtaagc aagaggtcag cagtttcttc ggacttcgag gtaaatggga
5581 tggaaagaaa ttgcgaaatg atgtgatatt ggcgattatg acactcttag gaggtgggtg
5641 gttcatgttg gaatacttca cgaaaaagat caatgaaccg gtgcgcgttg aaagcaagaa
5701 acgtcgatct caaaaattga aattcagggg tgcgtacgat agaaaagttg gacgtgagat
5761 ttttggatgat gatgatacaa ttgggcgac tttcggcgaa gcttacacga agagaggaaa
5821 ggtcaaagga aacaacaaca caaaaggaat gggacggaaa actcgcaatt ttgtgcattt
5881 atatggtgtg gagcctgaga attacagttt tatcagattt gtggaccctc tcaactggcca
5941 tacattggac gaaagcacc ccc atacagacat atcgtttagtg caggaggagt ttggaagtat
6001 tagagagaaa tttctggaga atgatttgat ctgcaggcag tctattatca acaaacccgg
6061 cattcaggca tattttatgg gcaagggcac tgaagaagca ctcaaagttg acttgactcc
6121 tcatgtacca ttgcttctgt gcagaaacac caatgctatt gcgggatacc cagagagaga
6181 aatgagtgtg agacaaactg gcacaccagt caaggtttct tttaaagacg tggcagagaa
6241 aaacgaacat gtcgagttgg agagcaaatc tatctacaaa ggagtgcgag attacaatgg
6301 catctcaaca atcgtttgtc aattaacgaa cgattctgat ggcctcaagg agaccatgta
6361 tggatttggc tatgggcca taatcatcac taatggacac ctcttcagga aaaacaatgg
6421 cacacttcta gtcaggtctt ggcaggtgta attcattgtt aaaaatacca caacgctcaa
6481 agtgcatttc atagaagggg aggatgtcgt gttagtgcgc atgccaaagg actttccgcc
6541 gtttaaaagc aacgcttctt ttagggcacc aaaacgcgag gaacgacgat gcttggttgg
6601 gacaaacttt caagaaaaga gtcttcgctc cactgtttcg gaatcttcca tgacaatacc
6661 tgaaggaact ggctcatatt ggatacattg gatttcgacc aacgaagggg attgctgatt
6721 gcccatgggt tcaacaacgg atggcaagat aattggagtt catggtttgg tttccacagt
6781 ctcatctaag aattattttg tcccattcac tgatgatttt atagccacgc atttgagcaa
6841 acttgatgac ctacatgga ctcagcattg gctatggcaa cctagcaaaa ttgctggtgg
6901 aacgctcaac ttagttgatg aacaaccagg gcccgatttt cgtatctcaa atctagtcaa
6961 ggatttattc acttctggtg ttgaaacaca gagcaagcga gaaagatggg tctacgaaag
7021 ctgtgaaggg aaccttcggg ctggttgaac tgcacaatca gcgttagtca ccaaacatgt
7081 tgtgaaaggg aagtgtcctt tcttcgaaga atattttacaa acacacgcag aagcgagcgc
7141 ctatttcaga cccctaattg gagagtacca gccgagcaag ttgaacaaag aagcctttaa
7201 aaaggatttc tttaaatata ataaacccgt cactgttaac caactggatc atgataaatt
7261 tttgggagca gtggatgggg ttatacgtat gatgtgtgat tttgagttca acgaatgtcg
7321 attcattaca gatcccagg aaattttacaa ctctttgaac atgaaagcag caaattggagc
7381 ccagtataga ggaaagaaga aagagtattt tgaggggcta gatgattttg atcgagagcg
7441 acttttattc caaagttgtg aaaggttgtt caatggctac aaaggtctgt ggaatggatc
7501 tttaaaggcc gagctcaggc cgcttgagaa agtcagggtt aacaaaacac gaacctttac
7561 agcagcgcca attgatacat tgcttggagc taaagtttgt gtggatgatt tcaacaatga
7621 gttctacagg aaaaacctca agtgtccatg gacggtcggc atgacaaaat tttatggtgg
7681 ttgggataaa ttgatgagat cattacctga tggttggttg tattgtcatg ctgatggatc
7741 acagttcgat agttcgttaa cccagcctt actgaacgca gtgctcataa tcaggtcatt
7801 ttatattggg gatgtgtggg tcggccaaga gatgcttgaa aatctttatg ccgagattgt
7861 gtacactcca attcttgctc ctgatggaac aattttcaag aaatttagag gtaacaacag
7921 tgggcaaccc tcaacagtgg tggataacac actaatggtt gtgatctcta tttactatgc

7981 gtgcatgaaa tttggttgga actgcgagga gattgagaat aaacttgtct tctttgcaaa
8041 tggagatgat ctgatacttg cagtcaaaga tgaggatagc ggcttacttg ataacatgtc
8101 atcctctttt tgcgaacttg gactgaatta tgatttttca gaacgtacgc ataaaagaga
8161 agatcttttg ttcatgtccc accaagcaat gctagttagt ggaatgtaca ctccaaaact
8221 cgagaaaagag agaattgttt caattctaga gtgggataga agcaaagaaa ttatgcaccg
8281 aacagaggct atttgcgctg cgatgattga ggcatggggg cacaccgagc tcttgcaaga
8341 aatcagaaag ttttacctat ggttcgttga aaaagaagag gtgcgagaat tggcagccct
8401 cggaaaagct ccatacatag ctgagacagc acttcgtaag ttatacactg acaagggagc
8461 agatacaagt gaactggcac gctacctaca agccctccat caagatatct tctttgagca
8521 aggagacact gtgatgctcc aatcaggcac tcagccaact gtggcagatg ctggagctac
8581 aaagaaagat aaagaagatg acaaagggaa aaacaaggac gttacaggct ccggctcagg
8641 tgagaaaaca gtagcagctg tcacgaagga caaggatgtg aatgctgggt ctcatgggaa
8701 aattgtgccg cgtcttttga agatcacaaa gaaaatgtca ttgccacgcg tgaaaggaaa
8761 tgtgatactc gatattgatc atttgctgga atataaaccg gatcaaattg agttatataa
8821 cacacgagcg tctcatcagc agttcgctc ttggttcaac caggttaaga cggaatatga
8881 tttgaacgag caacagatgg gagttgtaat gaatggtttc atggtttggt gcattgagaa
8941 tggcacttca cccgacatta atggagtgtg ggttatgatg gacggaaatg agcaagttga
9001 gtatcccttg aaaccaatag ttgaaaatgc aaagccaacg ctgcggcaaa taatgcatca
9061 tttttcagat gcagcggagg catatataga gatgagaaat gcagaggcac catacatgcc
9121 gaggtatggt ttgcttcgaa acctacggga taggagttta gcacgatatg cttttgattt
9181 ctatgaagtc aattctaaaa ctctgaaaag agcccgcgaa gctgttgcg cagatgaaagc
9241 agcagctctt agcaatgttt cttcaagggt gtttggcctt gatggaaatg ttgccaccac
9301 tagcgaagac actgaacggc aactgcacg tgatgttaat agaaacatgc acaccttact
9361 aggtgtgaat acaatgcagt aaagggtagg ccgcctacct aggttattgt ttcgctgccg
9421 acgtaattct aatatttacc gctttatttg atatctttag atttcagag tgggcctccc
9481 acctttaag cgtaaaagtt atgttagttg tccaggagtg ccgtagtcct ttcggaagct
9541 ttagtgtgag cctctcacga ataagctcga gattagactc cgtttgcaag cct

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12